|  Sign up!  


Return to Course Listing



CME: Therapeutic Updates, Best Practices, and Barriers to Care in the Management of Type 2 Diabetes Mellitus


Program Description / Statement of Need:

In this online CME self-learning program:

Type 2 diabetes mellitus (T2DM), the sixth leading cause of death in the U.S., is directly responsible for more then 73,000 deaths annually and is a contributing factor in more than 220,000 deaths.  More than 20 million Americans have diabetes of which 6 million are undiagnosed.  It is the leading cause of kidney failure and blindness in adults.  Evidence-based guidelines for the management of T2DM focus on three areas: lifestyle changes (that include diet, exercise and weight loss); management of cardiovascular disease risk factors (including hypertension, dyslipidemia and microalbuminuria with the use of aspirin, statins and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers); and management of blood glucose levels with pharmacotherapy. 


The Consensus Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes have identified a number of agents as either first- or later-line.  Partially in response to this Consensus Statement, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) convened a consensus panel and issued their statement on glycemic control in T2DM.  In developing their treatment algorithm, they set as priorities minimizing the risk and severity of hypoglycemia and minimizing the risk and magnitude of weight gain.   Consequently, the AACE/ACE Diabetes algorithm for glycemic control features a more prominent role for certain agents given their impact on weight and their relative risk of hypoglycemia.  The relatively recent nature of these guidelines’ updates implicitly suggests a practice gap that may be remedied by raising awareness through continuing education learning activities.


One other practical aspect highlighting a gap in care is one of demographic gaps in care.  The literature suggests that: there are or may be emerging or existing patterns of racial-, ethnic-, gender-, age-, and geographic-based disparities in healthcare and treatment of patients with T2DM; race- and ethnicity-based discrimination within the healthcare environment are associated with disparities in care; and that such discrimination is associated with both worse chronic health condition control and a higher incidence catastrophic health events.  Therefore, in addition to a therapeutic review, this program also attempts to examine the role of demographic-based barriers to care of patients with T2DM and strategies to minimize or alleviate those disparities.



  • Introduction, Disclosures
  • Definition, epidemiology, and risk factors for T2DM
  • Clinical and Diagnostic Features in T2DM
  • Treatment of T2DM
  • Summary, conclusions, and best practice recap


Target Audience:

Healthcare professionals who include certified diabetes educators, diabetes nurse educators, diabetologists, endocrinologists, family medicine practitioners, and those who otherwise commonly care for patients with diabetes or who frequently encounter them or their caregivers in practice.

Program Objectives:

By the end of the session the participant will be able to:

    • Be able to discuss the prevalence of T2DM in the U.S. and the growth of pre-diabetes, as well as the cost burdens that result from inadequate management of T2DM and its complications
    • Identify major co-morbidities associated with diabetes, including renal impairment.
    • Be able to understand appropriate testing of blood glucose, HBA1c, and other clinical markers
    • Describe the role of multifaceted approaches to attaining treatment goals including glycemic control, controlling weight, and reducing macrovascular and microvascular complications.
    • Recognize the appropriate therapeutic choices in individual patients based on their demographic and clinical characteristics


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.



    Release Date: December 12, 2012
    Expiration Date: December 12, 2014

    Faculty: Ann Lynch PharmD

    Faculty Disclosure and Resolution of COI:

    As an provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

    Faculty Disclosure: Ann Lynch, PharmD reports that she has no relevant financial disclosures.

    Disclosures of Educational Planner: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Novo Nordisk, the commercial supporter of this program.

    Commercial Support Disclosure: This program is supported by  educational grants from Novo Nordisk.


    Viewing Requirements:


    PC Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by  educational grants from Novo Nordisk.


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.